Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Kerry L, Arora, Shaily, Elayavilli, Ravikumar Komandur, Louv, William C, Schaller, Teilo H, Khandelwal, Aakanksha, Rothenberg, Mace, Khozin, Sean, Guidon, Amanda C, Dougan, Michael, Zubiri, Leyre, Petrillo, Laura, Sise, Meghan E, Villani, Alexandra-Chloe, Johnson, Douglas B, Rahma, Osama, Sharon, Elad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256840/
https://www.ncbi.nlm.nih.gov/pubmed/34215691
http://dx.doi.org/10.1136/jitc-2021-002896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256840/
https://www.ncbi.nlm.nih.gov/pubmed/34215691
http://dx.doi.org/10.1136/jitc-2021-002896

Ejemplares similares